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Abstract
Background: Systemic capillary leak syndrome is a rare condition characterized by episodic attacks of hypovolemia
due to systemic capillary hyperpermeability, which results in profound hypotension and edema. Although the
implication of vascular endothelial growth factor, angiopoietin-2, and C-X-C motif chemokine 10 has been suggested,
the pathogenesis of systemic capillary leak syndrome remains unclear. In this report, we describe a case of systemic
capillary leak syndrome in which serum isoform D of vascular endothelial growth factor was elevated. To the best of
our knowledge, this is the first reported case of systemic capillary leak syndrome in which isoform D of vascular
endothelial growth factor is suggested as the plausible biomarker.
Case presentation: A 41-year-old Japanese man was transferred to our emergency department. He was hypotensive,
tachycardic, and edematous over the trunk and all four limbs. He received aggressive intravenous fluid therapy and
underwent fasciotomy of the right forearm to prevent muscle necrosis. A diagnosis of systemic capillary leak syndrome
was suspected. The presence of serum monoclonal immunoglobulin G and κ light chain supported this diagnosis.
Prevention of hypotensive crises was unsuccessfully attempted with theophylline, intravenous immunoglobulin,
high-dose dexamethasone, bortezomib, melphalan, and prednisolone; however, the patient’s attacks dramatically
disappeared after the introduction of thalidomide. The serum of the patient was stored soon after the onset of
hypotensive crisis and analyzed to profile possible mediators responsible for the capillary leak. The concentration of
vascular endothelial growth factor, angiopoietin-2, and C-X-C motif chemokine 10 were all within normal ranges.
Meanwhile, we found that isoform D of vascular endothelial growth factor was elevated, which was normalized after
the introduction of thalidomide.
Conclusions: In our patient, isoform D of vascular endothelial growth factor (instead of vascular endothelial growth
factor) may have been a causative factor of hypotensive crises, since isoform D contributes to vascular endothelial
growth factor receptor-2 signaling, which is the major mediator of the permeability-enhancing effects of vascular
endothelial growth factor. We suggest the measurement of isoform D of vascular endothelial growth factor in patients
with systemic capillary leak syndrome in whose serum vascular endothelial growth factor is not elevated.
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Background
Systemic capillary leak syndrome (SCLS) is a rare condi-
tion characterized by episodic attacks of hypovolemia
due to systemic capillary hyperpermeability, which re-
sults in profound hypotension and edema. Acute attacks
of SCLS usually develop within a few hours and resolve
within 1–4 days. The stereotypic laboratory abnormal-
ities during acute attack are hemoconcentration (ele-
vated hematocrit) and hypoalbuminemia. The presence
of serum M protein during the quiescent phase between
the attacks is a notable common feature. Complications
such as acute renal failure, rhabdomyolysis, arrhythmia,
pericardial effusion, pleural effusion, deep venous throm-
bosis, and ischemic stroke during the attacks have been
reported [1, 2]. These complications can be directly re-
lated to death, and reported survival rates are 89% at 1
year and 73% at 5 years [1]. Although the implication of
vascular endothelial growth factor (VEGF), angiopoietin-2
(Ang-2), and C-X-C motif chemokine 10 (CXCL10) has
been suggested [3–6], the pathogenesis of SCLS remains
unclear.
Many agents have been tried sporadically with varying
degrees of effectiveness, including corticosteroids, intra-
venous immunoglobulin (IVIG), antihistamines, plasma-
pheresis, and β2-agonists (aminophylline, theophylline,
or terbutaline) [2]. The anti-VEGF monoclonal antibody
bevacizumab has been used successfully in one patient
[7]; however, the same anti-VEGF therapy was used in
another patient without success [3]. Thalidomide that
targets an abnormal plasma cell population or its se-
creted products has been used in some patients, with
improvement in symptoms achieved [1, 8].
In this report, we present a case of a man with SCLS
refractory to corticosteroids, theophylline, IVIG, borte-
zomib, melphalan, and prednisolone, whose attacks were
dramatically prevented by the introduction of thalido-
mide. We also demonstrate the elevated level of isoform
D of VEGF (VEGF-D) in this patient’s serum soon after
the hypotensive crisis. To the best of our knowledge, this
is the first reported case of SCLS in which VEGF-D is
suggested as the plausible biomarker.
Case presentation
A 41-year-old Japanese man was transferred to our
emergency department in October 2012 with complaints
of headache and nausea. He was hypotensive (98/57
mmHg), tachycardic (120–140 beats/minute), and edema-
tous over the trunk and all four limbs. He had experienced
the same episode 9 months previously. That first attack
had been complicated by stroke, which caused right hemi-
plegia. Laboratory studies demonstrated elevated levels of
hemoglobin (18.6 g/dl) and hematocrit (53.5%), as well as
hypoalbuminemia (2.2 g/dl). To keep his systolic blood
pressure from dropping below 60 mmHg, he was given
aggressive intravenous fluid therapy (500–1000 ml/hour).
Following hydration for more than 12 hours, he com-
plained of severe pain in his right forearm. His forearm
compartments were tense and swollen. He underwent fas-
ciotomy of the right forearm to prevent muscle necrosis.
A volar longitudinal incision was made. The patient’s
hypotension lasted for 2 days, and his symptoms reversed
quickly with massive diuresis. One week after fasciotomy,
the wound was closed.
In view of these clinical features, a diagnosis of SCLS
was suspected. Serum monoclonal immunoglobulin G
(IgG) and κ light chain was detected by immunofixation
electrophoresis, supporting this diagnosis. The patient’s
IgG level was 1143 mg/dl. A bone marrow study re-
vealed 1.0 % of plasma cells. These findings were con-
sistent with a monoclonal gammopathy of undetermined
significance. The clinical suspicion of angioedema was
not high, because the patient’s complement levels, such
as C4 and C1q, were all normal.
Prevention of these crises was attempted with theo-
phylline (400 mg/day), IVIG (2 g/kg/day for 1 day, re-
peated every 4 weeks), and high-dose dexamethasone
(40 mg on days 1–4, 9–12, and 17–20, repeated every 4
weeks); however, five additional episodes of hypotension
occurred in the subsequent 3 months after hospitalization
(Fig. 1). The last one was so severe that it required repeat
fasciotomy of the right forearm. Over the next 3 months,
seven episodes ensued despite VMP (bortezomib, melpha-
lan, and prednisolone) therapy, which consisted of borte-
zomib (1.3 mg/m2) on days 1, 8, 15, and 22 with
melphalan (9 mg/m2) and prednisolone (60 mg/m2) on
days 1–4. Then, daily oral thalidomide (100 mg) was
started. Surprisingly, the patient had no further episodes
for 2 years, except for one episode soon after the initiation
of thalidomide. Notably, his monoclonal IgG κ protein re-
mains clearly detectable, despite the complete disappear-
ance of his hypotensive crises.
The serum of the patient was stored on the 50th
hospital day, immediately after the onset of the 5th
hypotensive crisis, to profile possible mediators respon-
sible for the capillary leak. The second sample was
serum obtained on the 204th hospital day, when the pa-
tient’s hypotensive crisis had disappeared after the
introduction of thalidomide. The cytokine levels in the
patient’s serum were measured using Quantikine
enzyme-linked immunosorbent assay kits (R&D Systems,
Minneapolis, MN, USA). Our institutional review board
approved the study protocol, and written informed con-
sent was obtained from the patient.
First, we focused on VEGF, Ang-2, and CXCL10, since
the possible involvement of these cytokines in SCLS has
been indicated in some reports [3–6]. The results pre-
sented in Table 1 show that the concentrations of VEGF,
Ang-2, and CXCL10 were all within the normal range at
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each measurement point. Then, we analyzed VEGF iso-
forms VEGF-C and VEGF-D. The results were that the
concentration of VEGF-D on the 50th day was 1042 ng/
ml, which exceeded the normal range (135–642 ng/ml).
In the serum obtained on the 204th day as the negative
control, the VEGF-D level was normal. The concentra-
tions of VEGF-C did not exceed the normal range on
either the 50th or the 204th day. Supplemental examina-
tions of four more cytokines—interleukin (IL)-2, IL-4,
IL-6, and IL-11—were performed; however, none of
them was detected.
Discussion
The etiology of SCLS has not been clarified. One possi-
bility is a monoclonal immunoglobulin often detected in
the serum of patients. The clonal plasma cells may pro-
duce a toxic monoclonal immunoglobulin that causes
pathology by aggregating and depositing in tissue [9]. Al-
though purified monoclonal immunoglobulin from one
patient with SCLS failed to bind cultured endothelial
cells [3], we speculate that monoclonal immunoglobulin
should have an etiological function in some patients with
SCLS, because sometimes IVIG is quite effective as a
prophylactic therapy for hypotensive episodes [1]. IVIG
may neutralize pathogenic monoclonal immunoglobulin,
which is a widely accepted theory in treatment of im-
mune thrombocytopenic purpura. Although monoclonal
immunoglobulin was clearly detected after the dis-
appearance of the hypotensive crises by the introduction
of thalidomide, the possible involvement of monoclonal
immunoglobulin as an etiology in our patient could not
be ruled out.
Another plausible etiology is the soluble mediators. Re-
cently, three patients with SCLS were reported to have
high levels of plasma VEGF during acute episodes, which
decreased with symptom resolution [3, 5]. Further, Xie et
al. examined VEGF and Ang-2 in 20 patients with SCLS
and found that these were elevated in episodic SCLS sera
but not in remission sera [4]. Xie et al. also reported re-
cently that CXCL10 was significantly increased at baseline
and in acute SCLS sera relative to controls [6]. Meanwhile,
in episodic sera of our patient, not VEGF but its D iso-
form, VEGF-D, was detected. VEGF-D contributes to
VEGF receptor (VEGFR)-2 signaling, which is the major
mediator of the mitogenic, angiogenic, and permeability-
enhancing effects of VEGF [10]. Thus, VEGF-D, instead of
VEGF, may have been a causative mediator of hypotensive
crises in our patient. Further, VEGF-D signals through not
only VEGFR-2 but also VEFGR-3 (Flt-4). VEGF-D is
expressed in the vascular endothelium. VEFGR-3 is
expressed predominantly in lymphatic endothelial cells
and regulates lymphangiogenesis. VEGF-D has also been
implicated in lymphedema. We speculate that VEGF-D
may be involved in patients with SCLS whose serum
VEGF is not elevated [11] or in patients for whom anti-
VEGF antibody bevacizumab is not effective [3], since bev-
acizumab recognizes VEGF but not VEGF-D [12].
As this report is the first, to the best of our knowledge,
that names VEGF-D as a causative mediator, further
evaluation in more patients is necessary. Measuring
VEGF-D in serum soon after the hypotensive episode
Fig. 1 Clinical course of our patient. BP blood pressure, IVIG intravenous immunoglobulin, HD-Dex high-dose dexamethasone, VMP bortezomib,
melphalan, and prednisolone
Table 1 Cytokine levels in the patient’s serum
Our patient
Cytokines Healthy volunteersa, mean (range) (n) Day 50 Day 204
VEGF 220 (62–707) (n = 37) 97 221
Ang-2 2494 (1065–8907) (n = 60) 2266 1899
CXCL10 89 (38–361) (n = 60) 251 312
VEGF-C 4847 (2459–6651) (n = 30) 2133 4100
VEGF-D 297 (135–642) (n = 60) 1042 403
VEGF vascular endothelial growth factor, Ang-2 angiopoietin 2, CXCL10 C-X-C
motif chemokine 10, VEGF-C vascular endothelial growth factor-C, VEGD-D
vascular endothelial growth factor-D
Values are given in picograms per milliliter.
aThe data indicated in the manufacturer’s written instructions
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might be suggested in some patients with SCLS whose
serum VEGF, Ang-2, or CXCL-10 is not high.
As one more plausible etiology, we add the hypersensi-
tivity of VEGFR-2. We speculate that not only VEGF
concentration but also VEGFR-2 sensitivity regulates the
onset of SCLS, since patients with multiple myeloma
often have extremely elevated levels of serum VEGF con-
centration [13] without any symptoms of SCLS. Both
congenital and acquired factors are able to contribute to
the hypersensitivity of VEGFR-2. Genome-wide single-
nucleotide polymorphism (SNP) analysis of patients with
SCLS demonstrated that several SNPs were detected in
β-transducin repeat containing E3 ubiquitin protein lig-
ase and dysferlin, which could regulate VEGFR2 signal-
ing [14]. Further examination in these areas is needed.
There remains a problem regarding how thalidomide
controlled our patient’s VEGF-D-induced hypotensive
crises. Since thalidomide as a single agent achieves only
approximately 30% of overall response, with a complete
response rate probably in the 10% to at best 15% range
even in patients with proliferative myeloma, the eradica-
tion of clonal plasma cells with thalidomide in our pa-
tient could not be expected. A useful reference is a
report by Gupta et al., who demonstrated that thalido-
mide suppressed the production of VEGF from myeloma
cells and bone marrow stromal cells [15]. Also, in our
patient, thalidomide may have suppressed VEGF-D pro-
duction from clonal plasma cells or bone marrow stro-
mal cells.
There have been two reports presenting a total of four
patients with SCLS treated effectively with thalidomide
[1, 8]. Although we have no objection to the opinion of
Gousseff et al. that β2-agonists and IVIG provide
prophylaxis as the first-line therapy [8], there must be a
certain group of patients with SCLS who could be
treated effectively with thalidomide.
Conclusions
We present a case of SCLS with elevated serum
VEGF-D concentration whose hypotensive crises were
well-controlled with thalidomide.
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